Diabetes

View All

pharma-news-for-valneva-innovent-gsk-bayer
CEPI Grants $41.3 Million to Valneva; Innovent Achieves Phase III Success for Mazdutide; GSK’s BLENREP Combination Therapies EMA Review Application; Darolutamide Phase III ARANOTE Trial; Roche’s SUSVIMO Shows Long-Term Efficacy 

CEPI Grants $41.3 Million to Valneva to Enhance Global Access to First Chikungunya Vaccine The Coalition for Epidemic Preparedness Innovations and Valneva SE have expanded their partnership to enhance access to the world's first chikungunya vaccine, IXCHIQ®, in Low- and Middle-Income Countries (LMICs). CEPI will...

Find More

pharma-news-immutep-pfizer-novo-nordisk-arcutis
Immutep’ First-Line Treatment Positive Outcomes; Pfizer’s Once-Daily Oral GLP-1 Agonist Danuglipron; FDA Issues Complete Response Letter to Novo Nordisk; Arcutis’ ZORYVE® Cream 0.15% FDA Approval; NICE Recommends Ebglyss For Moderate To Severe Atopic Dermatitis

Immutep Announces Promising Outcomes for First-Line Treatment in PD-L1 Negative Head and Neck Squamous Cell Carcinoma Patients Immutep Limited announced positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial, evaluating eftilagimod alfa (efti) combined with MSD’s anti-PD-1 therapy KEYTR...

Find More

pharma-news-for-alnylam-bms-daichii-sankyo-vertex
Alnylam’s HELIOS-B Phase III Study of Vutrisiran; Bristol Myers Squibb Secures FDA Nod for KRAZATI and Cetuximab; Daichii Sankyo’s EZHARMIA® Receives Japan Approval; Vertex’s Phase I/II VX-880 Trial; argenx’s VYVGART Hytrulo FDA Approval

Alnylam's HELIOS-B Phase III Study of Vutrisiran Shows Positive Results, Meeting All Primary and Secondary Endpoints Alnylam Pharmaceuticals, Inc. reported encouraging topline outcomes from its HELIOS-B Phase III study of vutrisiran, an experimental RNAi therapy being developed to treat ATTR amyloidosis with car...

Find More

dietary-supplements-market-assessment
Nutrition Nexus: Illuminating the Growth Trajectory Path in the Dietary Supplements Market

The Dietary Supplements market has experienced significant growth over the past years, driven by a variety of factors contributing to its sustained demand. One primary reason for this surge is the increasing awareness and emphasis on preventive healthcare and wellness among consumers worldwide. As people become mor...

Find More

Prediabetes Treatment Landscape
Future Avenues for Prediabetes Treatment: The Road Ahead

Prediabetes is a significant health concern characterized by elevated blood sugar levels that fall between the normal range and the diagnostic threshold for type 2 diabetes. Often labeled as borderline diabetes, this metabolic condition is intricately linked to the global rise in obesity and poses an escalating wor...

Find More

Pharma News for Merck, Roche, AbbVie, Abbisko Pfizer
FDA Grants Priority Review to Merck’s Application for KEYTRUDA Plus Padcev; Roche and Carmot Therapeutics’s Definitive Merger Agreement; AbbVie to Acquire ImmunoGen; FDA Grants Orphan Drug Designation to LP-284; Merck Announces Commercialization Agreement With Abbisko; Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial

FDA Grants Priority Review to Merck’s Application for KEYTRUDA Plus Padcev for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Merck, operating as MSD internationally, reported that the U.S. Food and Drug Administration (FDA) has prioritized the review of a supplementar...

Find More

Insulin Pens Market Trends
Charting the Growth of the Insulin Pens Market Amidst Rising Demand

The evolution of technology has been a driving force behind the remarkable growth of the Insulin Pens market. Insulin Pens, from their inception as relatively basic delivery devices, have undergone a substantial transformation, becoming highly advanced and user-friendly tools. In the early stages, these pens requir...

Find More

MedTech News for Orthofix, Medtronic, MicroVention
Orthofix Launched the Galaxy Fixation Gemini System; Oxford Biodynamics Launched the EpiSwitch Prostate Screening Blood Test; CE Mark for the Medtronic’s New Simplera CGM; FDA 510(k) Clearance to MicroVention’s SOFIA™ EX 5F 115cm; SHL Telemedicine’s SmartHeart® Technology; Cardiosense’s Nationwide Heart Failure Study

Orthofix Launched the Galaxy Fixation Gemini System and Expanded Sterile Kit Offerings for Orthopedic Trauma Procedures On September 20, 2023, Orthofix Medical Inc., a leading global spine and orthopedics company, launched the Galaxy Fixation Gemini™ system.  It is a stable external fixation system that ...

Find More

Smart Medical Devices Market Outlook
The Revolution of Healthcare: Smart Medical Devices Transforming the Future

It is not surprising that the healthcare sector is undergoing a significant transition in an era characterized by technological developments and the digitization of almost every aspect of our lives. The development of smart medical devices is a shining illustration of how technology has advanced in healthcare in a ...

Find More

cell-and-gene-therapies-for-diabetes-treatment
Cell and Gene Therapies for Diabetes Treatment: A Permanent Cure for Patients?

Diabetes is the 8th largest cause of death in the United States (although its prevalence may be underreported). Diabetes affects more than 37 million people in the United States, and 1 in every 5 are unaware of their condition. Over 96 million US adults—more than one-third—have prediabetes, and more than 8 out of 1...

Find More